Gynecologic Oncology, Minimally Invasive Surgery, Complex Gynecologic problems, Preinvasive disease of the
lower anogenital tract
Hospital Affiliation
University Hospital, Newark St. Clare's Hospital Newark Beth Israel Medical Center
INSURANCE PARTICIPATION
Insurance Participation: with Provider Number (where applicable) The information below is subject to change and should not be relied upon until after
it is verified with the insurance company. In addition, psychiatric providers should
be contacted directly for information on their participation with managed care and
insurance companies.
Mark H. Einstein, MD, MS, FACS, FACOG is Professor and Chair of Obstetrics, Gynecology and Women?s Health
at Rutgers New Jersey Medical School. Dr. Einstein is a Gynecologic Oncologist who is an expert at identification
and treatment of gynecologic malignancies. His primary research interests focus on the pathogenesis, therapy,
and prevention of lower anogenital tract and gynecologic cancers. He leads numerous clinical efforts identifying
unique targets and biomarkers for clinical risk of malignant transformation. He is also testing many novel drugs
for cancer treatment. He has been an active leader for management guidelines and translating clinical trial and
translational data for such organizations as the World Health Organization (WHO), American Cancer Society
(ACS), Society of Gynecologic Oncology (SGO), American College of Obstetrics and Gynecology (ACOG), and
Society of Lower Genital Tract Disease (ASCCP). He serves on the Boards for SGO and the ASCCP. He has
served on numerous committees and leadership for the National Cancer Institute (NCI)-funded NRG Oncology
group and AIDS Malignancy Consortium (AMC). Currently, he serves as a principal investigator on many multi-
institutional clinical trials for gynecologic cancers in the US and Internationally. He has been funded for his
research efforts by a number of organizations including the NCI, ACS, Foundation for Women?s Cancers, and
others.
Education
M.D., 1995, University of Miami M.S., 2005, Albert Einstein College of Medicine, Yeshiva University B.S., 1989, University of Miami
Licensure & Certification
Medical Licensure New Jersey
Areas Of Interest
1. My translational work in cervical cancer is multi-faceted. I have investigating the host and virally-induced
epigenetic, genetic and immune profiles along the malignant transformation path to provide insight into the
process of cervical carcinogenesis.
? Einstein MH, Kadish AS, Burk RD, Kim MY, Wadler SS, Streicher H, Goldberg GL, Runowicz CD. Heat Shock
Fusion Protein-Based Immunotherapy (HspE7) for Treatment of Cervical Intraepithelial Neoplasia (CIN) III (NCI
5850). Gynecol Oncol. 106(3): 453-460. 2007. PMID: 17586030. *Clinicaltrials.gov NCT00075569
? Einstein MH, Leanza S, Chiu L, Schlecht N, Goldberg GL, Steinberg B, Burk RD. Genetic Variants in TAP are
associated with High-Grade Cervical Neoplasia. Clinical Cancer Research. 15(3): 1019-1023. 2009. PMID:
19188174
2. I am an active member of National Cooperative Groups (NRG Oncology, nCORP) Additionally, I am leading the
AMC efforts in cervical cancer treatment in sub-Saharan Africa.
? Einstein MH, Novetsky AP, Garg M, Hailpern SM, Huang GS, Fields AL, Kalnicki S, Goldberg GL. Survival
and Toxicity Differences between 5-day and Weekly Cisplatin Concomitant with External Beam Radiotherapy
and High Dose Rate Brachytherapy in Patients with Locally-Advanced Cervical Cancer. Cancer. 2007. Jan
1;109(1):48-53. PMID: 17123270
? Einstein MH, Frimer M, Kuo DYS, Reimers LL, Mehta K, Mutyala S, Huang GS, Hou JY, Goldberg GL,
Prospective phase II trial of adjuvant pelvic radiation ?sandwiched? between combination paclitaxel,carboplatin
chemotherapy n women with uterine papillary serous carcinoma. Gynecol Oncol. 124: 21-25. 2012. PMID:
22035806. *Clinicaltrials.gov NCT00231868
? Einstein MH, Klobocista M, Hou JY, Lee S, Mutyala S, Mehta K, Reimers LL, Kuo DYS, Huang GS, Goldberg
GL. Phase II Trial of Adjuvant Pelvic Radiation ?Sandwiched? Between Ifosfamide or Ifosfamide plus Cisplatin in
Women with Uterine Carcinosarcoma. Gynecol Oncol. 124: 26-30. 2012. PMID:22055846 *Clinicaltrials.gov
NCT0023184
3. I have been active in translating clinical trial and translational data into clinical practices regarding cervical
cancer prevention including being a Member of the Steering Committee for the American Society for Colposcopy
and Cervical Pathology (ASCCP) Cervical Screening and Management Guidelines.
? Saslow D et al. (Einstein MH is one of 86 collaborators). American Cancer Society, American Society for
Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the
prevention and early detection of cervical cancer. CA Cancer J Clin. 62(3): 147-72. 2012. PMID: 22422631 and J
Low Genit Tract Dis. 2012 Jul;16(3):175-204. PMID: 22418039
? Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson
HW. Updated Guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.
Obstetrics & Gynecology. 121(4): 829-46. 2013. PMID: 23635684.
4. As a consultant to the World Health Organization (WHO), I have helped developed their modules on the
immunologic basis of HPV vaccines, and harmonizing with current cervical cancer screening.
? Einstein, MH. Immunological Basis of Human Papillomavirus Vaccines. Immunological Basis for
Immunization Series. World Health Organization. Geneva, Switzerland. 2011.
http://whqlibdoc.who.int/publications/2011/9789241501590_eng.pdf.
